RGEN - Repligen's Strong Q3 Recovery: CEO Says Pharma Orders Rebound Analytics Business Grows | Benzinga
Repligen Corporation (NASDAQ: RGEN) reported third-quarter (Q3) revenues of $141.19 million, down 30% Y/Y, beating the consensus of $140.64 million.
The company's Q3 adjusted EPS reached 23 cents, beating the consensus of 17 cents and down 77 cents a year ago.
For Q3 2023, base business accounted for approximately 99% of total revenue. There was no COVID-related revenue in the quarter, compared to approximately $29 million for Q3 2022.
Adjusted income from operations for Q3 2023 was $5.2 million, compared to $58.2 million for Q3 2022.
In October, Repligen completed the acquisition of Metenova for $164 million in cash and $9 million in equity consideration.
"While the broader challenges ...